Organization
Istituto Nazionale Tumori-IRCCS Fondazione G. Pascale
3 abstracts
Abstract
Intermittent or continuous panitumumab plus FOLFIRI (FOLFIRI/PANI) for first-line treatment of patients (pts) with RAS/BRAF wild-type (wt) metastatic colorectal cancer (mCRC): An update of survival/toxicity and preliminary results of genomic alterations from IMPROVE study.Org: Istituto Nazionale Tumori-IRCCS Fondazione G. Pascale, National Cancer Research Centre, Istituto Tumori “Giovanni Paolo II”, Istituto Nazionale Tumori Fondazione G. Pascale, AORN DEI Colli - Monaldi Hospital,
Abstract
RAS testing of circulating cell-free DNA (cfDNA) from tissue RAS/BRAF wild-type metastatic colorectal carcinoma (mCRC) patients: Preliminary data from the Liquid Biopsy Monoclonal Antibodies in mCRC (LIBImAb) study.Org: Cell Biology and Biotherapy Unit, Istituto Nazionale Tumori – IRCCS Fondazione G. Pascale, Napoli, Italy, Istituto Nazionale Tumori-IRCCS Fondazione G. Pascale, Istituto Nazionale Tumori - IRCCS Fondazione Pascale, Medical Oncology Unit. Comprehensive Cancer Center. AUSL-IRCCS Reggio Emilia, Department of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) “Dino Amadori”, Meldola, Italy, Italy,
Abstract
Nature and management of melanoma recurrences following adjuvant anti-PD-1 (PD1) therapy.Org: Melanoma Institute Australia, Netherlands Cancer Institute (NKI), Department of Dermatology, APHP St Louis, Alfred Health,